Clinical Trial Update: SGLT2 Inhibition in Diabetes and Heart Failure

View source ↗

Summary

The trial update indicates completion of a study evaluating SGLT2 inhibitors in patients with type 2 diabetes mellitus and systolic heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Diabetes Mellitus, Type 2, Heart Failure, Systolic | Status: COMPLETED